Advertisement

Impact of Nonalcoholic Fatty Liver Disease on Myocardial Perfusion in Nondiabetic Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction

Published:October 02, 2015DOI:https://doi.org/10.1016/j.amjcard.2015.09.021
      Limited data exist on the role of nonalcoholic fatty liver disease (FLD) as a potential independent risk factor in the setting of acute coronary syndromes. The aim of this study was to evaluate the impact of FLD on myocardial perfusion and inhospital major adverse cardiac events (MACE) in the setting of ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). We examined 186 consecutive nondiabetic patients (mean age 58 ± 11 years and 76% men) who underwent primary PCI for STEMI by ultrasound within 72 hours of admission. FLD was graded according to a semiquantitative severity score as mild (score <3) or moderate to severe (score ≥3). Myocardial perfusion was determined by measuring myocardial blush grade (MBG) and ST-segment resolution (STR) analysis. Patients were divided into 2 groups according to FLD score (<3 or ≥3). There were no differences with regard to postprocedural Thrombolysis In Myocardial Infarction 3 flow grade between the 2 groups (89% vs 83%, p = 0.201). Patients with FLD score ≥3 were more likely to have absent myocardial perfusion (MBG 0/1, 37% vs 12%, p <0.0001), absent STR (27% vs 9%, p = 0.001), and higher inhospital MACE rate (31% vs 8%, p <0.0001). By multivariate analysis, FLD ≥3 score was found to be an independent predictor of absent MBG 0/1 (odds ratio [OR] 2.856, 95% confidence interval [CI] 1.214 to 6.225, p = 0.033), absent STR (OR 2.862, 95% CI 1.242 to 6.342, p = 0.031), and inhospital MACE (OR 2.454, 95% CI 1.072 to 4.872, p = 0.048). In conclusion, we found that despite similar high rates of Thrombolysis In Myocardial Infarction 3 after primary PCI, patients with FLD score ≥3 are more likely to have impaired myocardial perfusion which may contribute to adverse inhospital outcome.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tarquini R.
        • Lazzeri C.
        • Boddi M.
        • Marra F.
        • Abbate R.
        • Gensini G.F.
        Non-alcoholic fatty liver disease: a new challenge for cardiologists.
        G Ital Cardiol. 2010; 11: 660-669
        • Targher G.
        • Day C.P.
        • Bonora E.
        Risk of cardiovascular disease in patients with non-alcoholic fatty liver disease.
        N Engl J Med. 2010; 363: 1341-1350
        • Oni E.T.
        • Agatston A.S.
        • Blaha M.J.
        • Fialkow J.
        • Cury R.
        • Sposito A.
        • Erbel R.
        • Blankstein R.
        • Feldman T.
        • Al-Mallah M.H.
        • Santos R.D.
        • Budoff M.J.
        • Nasir K.
        A systematic review of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?.
        Atherosclerosis. 2013; 230: 258-267
        • Byrne C.D.
        • Olufadi R.
        • Bruce K.D.
        • Cagampang F.R.
        • Ahmed M.H.
        Metabolic disturbances in nonalcoholic fatty liver disease.
        Clin Sci (Lond). 2009; 116: 539-564
        • Bathia L.S.
        • Curzen N.P.
        • Calder P.C.
        • Byrne C.D.
        Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor.
        Eur Heart J. 2012; 33: 1190-1200
        • Boddi M.
        • Tarquini R.
        • Chiostri M.
        • Marra F.
        • Valente S.
        • Giglioli C.
        • Gensini G.F.
        • Abbate R.
        Nonalcoholic fatty liver in nondiabetic patients with acute coronary syndromes.
        Eur J Clin Invest. 2013; 43: 429-438
        • Henriques J.P.S.
        • Zijlstra F.
        • Van't Hof A.W.J.
        • de Boer M.J.
        • Dambrink J.H.E.
        • Gosselink M.
        • Hoomtje J.C.A.
        • Suryapranata H.
        Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade.
        Circulation. 2003; 107: 2115-2119
        • De Lemos J.A.
        • Braunwald E.
        ST segment resolution as a tool for assessing the efficacy of reperfusion therapy.
        J Am Coll Cardiol. 2001; 38: 1283-1294
        • Van't Hof A.W.
        • Liem A.
        • Suryapranata H.
        • Hoomtje J.C.
        • de Boer M.J.
        • Zijlstra F.
        Zwolle. Myocardial Infarction Study Group. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade.
        Circulation. 1998; 97: 2302-2306
        • Hamaguchi M.
        • Kojima T.
        • Itoh Y.
        • Harano Y.
        • Fujii K.
        • Nakajima T.
        • Kato T.
        • Takeda N.
        • Okuda J.
        • Ida J.
        • Kawahito Y.
        • Yoshikawa T.
        • Okanoue T.
        The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation.
        Am J Gastroenterol. 2007; 102: 2708-2715
        • Bedogni G.
        • Kahn H.S.
        • Bellentani S.
        • Tribelli C.
        A simple index of lipid overaccumulation is a good marker of liver steatosis.
        BMC Gastroenterol. 2010; 10: 98-106
        • Needleman L.
        • Kurtz A.B.
        • Rifkin M.D.
        • Cooper H.S.
        • Pasto M.E.
        • Goldberg B.B.
        Sonography of diffuse benign liver disease accuracy of pattern recognition and grading.
        Am J Roentgenol. 1986; 146: 1011-1015
        • Eapen Z.J.
        • Tang W.H.
        • Felker G.M.
        • Hernandez A.F.
        • Mahaffey K.W.
        • Lincoff A.M.
        • Roe M.T.
        Defining heart failure endpoints in ST segment elevation myocardial infarction trials: integrating past experiences to chart a path forward.
        Circ Cardiovasc Qual Outcomes. 2012; 5: 594-600
        • The Gusto Angiographic Investigators
        The effects of tissue plasminogen activator, streptokinase or both on coronary-artery patency, ventricular function and survival after acute myocardial infarction. The Gusto Angiographic Investigators.
        N Engl J Med. 1993; 329: 1615-1622
        • Niccoli G.
        • Burzotta F.
        • Galiuto L.
        • Crea F.
        Myocardial no-reflow in humans.
        J Am Coll Cardiol. 2009; 54: 281-292
        • Iliceto S.
        • Marangelli V.
        • Marchese A.
        • Amico A.
        • Galiuto L.
        • Rizzon P.
        Myocardial contrast echocardiography in acute myocardial infarction. Pathophysiological background and clinical applications.
        Eur Heart J. 1996; 17: 344-353
        • Hayat S.A.
        • Senior R.
        Myocardial contrast echocardiography in ST elevation myocardial infarction: ready for prime time?.
        Eur Heart J. 2008; 29: 299-314
        • Mega J.L.
        • Braunwald E.
        • Wiviott S.D.
        • Bassand J.P.
        • Bhatt D.L.
        • Bode C.
        • Burton P.
        • Cohen M.
        • Cook-Bruns N.
        • Fox K.A.
        • Goto S.
        • Murphy S.A.
        • Plotnikov A.N.
        • Schneider D.
        • Sun X.
        • Verheught F.W.
        • Gibson C.M.
        • ATLAS ACS 2-TIMI 51 Investigators
        Rivaroxaban in patients with a recent acute coronary syndrome.
        N Engl J Med. 2012; 366: 9-19
        • Wallentin L.
        • Becker R.C.
        • Budaj A.
        • Cannon C.P.
        • Emanuelsson H.
        • Held C.
        • Horrow J.
        • Husted S.
        • James S.
        • Katus H.
        • Mahaffey K.W.
        • Scirica B.M.
        • Skene A.
        • Steg P.G.
        • Storey R.F.
        • Harrington R.A.
        • Freij A.
        • Thorsen M.
        • PLATO Investigators
        Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2009; 361: 1045-1057
        • Hasdai D.
        • Topol E.J.
        • Kilaru R.
        • Battler A.
        • Harrigton R.A.
        • Vahanian A.
        • Ohman E.M.
        • Granger C.B.
        • van de Werf F.
        • Simoons M.L.
        • O'connor C.M.
        • Holmes Jr., D.R.
        Frequency, patient characteristics and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials.
        Am Heart J. 2003; 145: 73-79
        • Day C.P.
        From fat to inflammation.
        Gastroenterology. 2006; 130: 207-210
        • Shoelson S.E.
        • Herrero L.
        • Naaz A.
        Obesity, inflammation and insulin resistance.
        Gastroenterology. 2007; 132: 2169-2180
        • Stefan N.
        • Kantartzis K.
        • Haring H.U.
        Causes and metabolic consequences of fatty liver.
        Endocr Rev. 2008; 29: 939-960
        • Tilg H.
        • Moschen A.R.
        Insulin resistance, inflammation and nonalcoholic fatty liver disease.
        Trends Endocrinol Metab. 2008; 19: 371-379
        • Targher G.
        • Chonchol M.
        • Miele L.
        • Zoppini G.
        • Pichiri I.
        • Muggeo M.
        Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome.
        Semin Thromb Hemost. 2009; 35: 277-287
        • Villanova N.
        • Moscatiello S.
        • Ramilli S.
        • Bugianesi E.
        • Magalotti D.
        • Vanni E.
        • Zoli M.
        • Marchesini G.
        Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease.
        Hepatology. 2005; 42: 473-480
        • Iacobellis G.
        • Barbarini G.
        • Letizia C.
        • Barbaro G.
        Epicardial fat thickness and nonalcoholic fatty liver disease in obese patients.
        Obesity. 2014; 22: 332-336
        • Tadros T.M.
        • Massaro J.M.
        • Rosito G.A.
        • Hoffmann U.
        • Vasan R.S.
        • Larson M.G.
        • Keaney Jr., J.F.
        • Lipinska I.
        • Meigs J.B.
        • Kathiresan S.
        • O'Donnell C.J.
        • Fox C.S.
        • Benjamin E.J.
        Pericardial fat volume correlates with inflammatory markers: the Framingham Heart Study.
        Obesity. 2010; 18: 1039-1045
        • Athyros V.G.
        • Tziomalos K.
        • Gossios T.D.
        • Griva T.
        • Anagnostis P.
        • Kargiotis K.
        • Pagourelias E.D.
        • Theocharidou E.
        • Karagiannis A.
        • Mikhailidis D.P.
        • GREACE Study Collaborative Group
        Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.
        Lancet. 2010; 376: 1916-1922

      Linked Article